Fulcrum Therapeutics (FULC) Retained Earnings (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Retained Earnings of -$513000.0 for Q1 2026, down 832.86% year-over-year from $70000.0 in Q1 2025, and down 394.83% quarter-over-quarter from $174000.0 in Q4 2025.
Fulcrum Therapeutics (FULC) Retained Earnings (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Retained Earnings data on file, last reported at -$513000.0 in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$513000.0, down 832.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$513000.0 (down 832.86% YoY), and the FY2025 annual result was $174000.0, up 100.03% from the prior year.
- Retained Earnings retreated to -$513000.0 in Q1 2026 per FULC's latest filing, from $174000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $241000.0 in Q3 2025 and troughed at -$536.5 million in Q1 2024.
- A 5-year average of -$191.7 million and a median of -$1.1 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings plunged 4027677.78% in 2022, then surged 122.4% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$797000.0 in 2022, then slumped by 63848.93% to -$509.7 million in 2023, then decreased by 1.91% to -$519.4 million in 2024, then soared by 100.03% to $174000.0 in 2025, then slumped by 394.83% to -$513000.0 in 2026.
- Business Quant data shows FULC's Retained Earnings at -$513000.0 in Q1 2026, $174000.0 in Q4 2025, and $241000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -838.07 Mn |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | -513,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -513,000.00 |
| Dec 31, 2025 | 174,000.00 |
| Sep 30, 2025 | 241,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Mar 31, 2025 | 70,000.00 |
| Dec 31, 2024 | -519.40 Mn |
| Sep 30, 2024 | -502.83 Mn |
| Jun 30, 2024 | -366,000.00 |
| Mar 31, 2024 | -536.50 Mn |
| Dec 31, 2023 | -509.67 Mn |
| Sep 30, 2023 | -886,000.00 |
| Jun 30, 2023 | -1.20 Mn |
| Mar 31, 2023 | -437.12 Mn |
| Dec 31, 2022 | -797,000.00 |
| Sep 30, 2022 | -386.20 Mn |
| Jun 30, 2022 | -362.50 Mn |
| Mar 31, 2022 | -1.09 Mn |
| Dec 31, 2021 | -302.47 Mn |
| Sep 30, 2021 | -87,000.00 |
| Jun 30, 2021 | -9,000.00 |